1. A compressed tablet for oral administration which comprises:(A) intragranular component comprising:(I) an effective amount of an alkali metal salt raltegravir,(Ii) optionally, a first superrazryhlitel and(Iii) a binding agent and(B) an extragranular component comprising:(I) second superrazryhlitel,(Ii) a filler, and(Iii) a lubricantwith the proviso that the tablet does not include atazanavir or a pharmaceutically acceptable salt thereof.2. A compressed tablet according to claim 1, wherein:(A) (i) alkali metal salt used for raltegravir free phenol basis in an amount of at least about 30 wt.%(A) (ii) first superrazryhlitel used in an amount ranging from zero to about 12 wt.%(A) (iii) a binding agent is used in an amount ranging from about 0.5 wt% to about 7 wt.%.(B) (i) a second superrazryhlitel used in an amount ranging from about 3 wt% to about 20 wt.%.(B) (ii) the filler is used in an amount ranging from about 10 wt% to about 40 wt.%. and(B) (iii) a lubricating agent is used in an amount ranging from about 0.5 wt% to about 2.5 wt.%.superrazryhlitelya wherein the total amount is in the range from about 6 wt% to about 20 wt.%. andwherein the weight percent of each ingredient in a compressed tablet based on the total weight of the compressed tablet.3. The compressed tablet for oral administration of claim 1, wherein the first superrazryhlitel present in intragranular component A.4. A compressed tablet according to claim 3, wherein:(A) (i) alkali metal salt used for raltegravir free phenol basis in an amount of at least about 30 wt.%(A) (ii) first superrazryhlitel used in an amount ranging from about 3 wt% to about 12 wt.%.(A) (iii) a binding agent is used in an amount ranging from about 0.5 wt% to about 7 wt.%.(B) (i) a second superrazryhlitel used in an amount ranging from about 3 wt% to about 15 wt.%.(B) (ii) the filler is used in an amount ranging from about 10 wt% to about 40 wt.%. and(B) (iii) a lubricating agent is used in an amount ranging from about 0.5 wt%
